Search This Blog

Thursday, November 19, 2026

Marker Therapeutics won a $16.2 million CPRIT grant to support Phase 2 development

of MT-601 in its APOLLO lymphoma study.

https://finviz.com/stock?t=MRKR&p=d

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.